KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.96

Darolutamide in Spanish patients with nonmetastatic castration-resistant prostate cancer: ARAMIS subgroup analysis.

Joan Carles, Rafael A Medina-Lopez, Javier Puente, Álvaro Gómez-Ferrer, Javier Casas Nebra, María Isabel Sáez Medina, Maria J Ribal, Alfredo Rodríguez Antolín, José Luís Álvarez-Ossorio, José Francisco Suárez Novo, Cristina Moretones Agut, Shankar Srinivasan, Jorge Ortiz, Karim Fizazi

Future Oncol 19(12) 819-828

PMID37222151
PMCID-
DOI10.2217/fon-2022-1131
发表日期2023-05-24
入排依据:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
摘要

摘要

Aim: Darolutamide significantly prolonged metastasis-free survival (MFS) versus placebo in the Phase III ARAMIS study. We analyzed outcomes in Spanish participants in ARAMIS. Patients & methods: Patients with high-risk nonmetastatic castration-resistant prostate cancer were randomized 2:1 to darolutamide 600 mg twice daily or placebo, plus androgen-deprivation therapy. The primary end point was MFS. Descriptive statistics are reported for this post hoc analysis. Results: In Spanish participants, darolutamide (n = 75) prolonged MFS versus placebo (n = 42): hazard ratio 0.345, 95% confidence interval 0.175-0.681. The incidence and type of treatment-emergent adverse events were comparable between treatment arms. Conclusion: For Spanish participants in ARAMIS, efficacy outcomes favored darolutamide versus placebo, with a similar safety profile, consistent with the overall ARAMIS population. Clinical Trials Registration: NCT02200614 (ClinicalTrials.gov).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。